Carmustine implants for glioma - horizon scanning review

Record ID 32002000533
Authors' objectives:

To summarise the available evidence on carmustine implants for glioma.

Authors' recommendations: - Clinical impact: The clinical impact associated with the introduction of carmustine implants is significant. Over the course of a recent 30-month study in patients undergoing initial surgery for primary glioblastoma multiforme, a 33% reduction in the risk of death was demonstrated. Any hope that can be offered for this patient population, which has a 5-year survival of less than 5%, is important. - Service impact: While there may be some service impact due to the need to train surgeons to implant carmustine implants, the standard procedures used in a craniotomy are maintained. - Additional factors: Patients with glioma have an extremely poor prognosis. As such, it is likely that this treatment will generate significant professional and patient interest. - Financial and overall NHS impact: While pricing has not yet been set, the incremental cost for carmustine implants is expected to be in the range of 625 to 675 GBP per life week saved (USA data).
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Drug Implants
  • Antineoplastic Agents
  • Brain Neoplasms
  • Carmustine
  • Glioblastoma
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.